Trastuzumab rezetecan extends progression-free survival in HER2-positive metastatic colorectal cancer

◆ TRIAL DATA

The phase III HORIZON-CRC-01 trial showed median progression-free survival of 5.5 months with the antibody-drug conjugate versus 2.8 months with standard care, a 67% reduction in risk of progression or death in chemotherapy-refractory patients. (The ASCO Post)